EUVIMEDEUVIMED entdecken
Crossref

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment

Haidi Sun, Li Han, Hongwei Wu, Hongsheng Xue, Ming-Fei Lang, Jingyu Tan

Pulmonary Pharmacology & Therapeutics · 2026-06 · 93 · 102422

DOI: 10.1016/j.pupt.2026.102422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026-06. Verfasst von Haidi Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121012, China; Medical College, Dalian University, Dalian, Liaoning, …. Hauptthemen laut MEDLINE: Flavonoids, Artemisinins, Lung Neoplasms, DNA Topoisomerases, Type II. Die Arbeit nennt 50 Literaturangaben. Gefördert von: First Affiliated Hospital of Jinzhou Medical University, Higher Education Discipline Innovation Project, Dalian University Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains a leading healthcare challenge due to its high mortality and incidence. To develop a new therapeutic approach, dihydroartemisinin (DHA) was combined with chrysin (CRS) to test their effects on both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells. The results demonstrated that the DHA + CRS combination not only significantly reduced the effective concentrations of both drugs but also robustly induced apoptosis in both cancer types. Utilizing next-generation sequencing, topoisomerase II alpha (TOP2A) was identified as a critical molecular target mediating the apoptosis-enhancing effects of this combination therapy. Validation experiments, including TOP2A overexpression and siRNA-mediated silencing, confirmed TOP2A's pivotal role in the apoptotic pathway activated by DHA + CRS. Mechanistically, the combination therapy reduced TOP2A expression, leading to DNA damage accumulation (evidenced by increased γH2A.X) and p53 upregulation. This study established a novel therapeutic strategy for treating the two major lung cancer subtypes by DHA and CRS combination at lower concentrations. The discovery of TOP2A as a therapeutic target opens new avenues for drug discovery, potentially expanding the development of TOP2A-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonoidsArtemisininsLung NeoplasmsDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsAntineoplastic Combined Chemotherapy ProtocolsHumansApoptosisDNA DamageCell Line, TumorDrug SynergismSmall Cell Lung CarcinomaRNA, Small Interfering

Stichwörter der Autor:innen

ChrysinCombination therapyDihydroartemisininLung cancerTOP2A

Substanzen

FlavonoidsartenimolArtemisininsTOP2A protein, humanchrysinDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsRNA, Small Interfering

Autor:innen und Institutionen

  • The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121012, China; Medical College, Dalian University, Dalian, Liaoning, 116622, China.
  • Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.
  • School of Software Engineering, Dalian University, Dalian, Liaoning, 116622, China. Electronic address: wuhongwei@dlu.edu.cn.
  • Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China. Electronic address: xuehongsheng1235@163.com.
  • Medical College, Dalian University, Dalian, Liaoning, 116622, China. Electronic address: langmingfei@dlu.edu.cn.
  • The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121012, China. Electronic address: tanjingyu2023@163.com.

Förderung

  • First Affiliated Hospital of Jinzhou Medical University
  • Higher Education Discipline Innovation Project
  • Dalian University Medical College
  • Natural Science Foundation of Liaoning Province
  • Department of Education of Liaoning Province

Zitieren

APA

Sun, H., Han, L., Wu, H., Xue, H., Lang, M. F., & Tan, J. (2026). Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment. Pulmonary Pharmacology & Therapeutics, 93, 102422. https://doi.org/10.1016/j.pupt.2026.102422

Vancouver

Sun H, Han L, Wu H, Xue H, Lang MF, Tan J. Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment. Pulmonary Pharmacology & Therapeutics. 2026;93:102422. doi:10.1016/j.pupt.2026.102422

BibTeX
@article{Sun2026,
  author = {Sun, Haidi and Han, Li and Wu, Hongwei and Xue, Hongsheng and Lang, Ming-Fei and Tan, Jingyu},
  title = {Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment},
  journal = {Pulmonary Pharmacology & Therapeutics},
  year = {2026},
  volume = {93},
  pages = {102422},
  doi = {10.1016/j.pupt.2026.102422}
}
Kostenlos starten →